Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Document › Details

Kiadis Pharma N.V.. (10/17/19). "Press Release: Kiadis Pharma Provides Regulatory Update on ATIR101". Amsterdam.

Region Region EU (European Union)
Organisations Organisation Kiadis Pharma N.V. (Euronext: KDS)
  Group Kiadis (Group)
  Organisation 2 CHMP (Committee for Medicinal Products for Human Use) (EU)
  Group EU (govt)
Products Product ATIR101™ (Kiadis)
  Product 2 phase 2 study
Persons Person Lahr, Arthur (Kiadis 201704– CEO before Crucell 200701 Chief Strategy Officer + EP Sales + BusDev)
  Person 2 Holmes, Scott A. (Kiadis 201901– CFO before Keryx Biopharmaceuticals + AMAG Pharmaceuticals + Molecular Biometrics)

> Kiadis no longer expects EU conditional marketing authorization for ATIR101 in 2020

> Kiadis plans to refile at the conclusion of the ongoing phase 3 trial

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it no longer expects to receive EU conditional marketing authorization for ATIR101 in 2020. The Company expects that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) will issue a negative opinion and recommend against conditional marketing authorization at the next CHMP meeting in November 2019.

Arthur Lahr, CEO of Kiadis Pharma commented, “Today’s news is very disappointing, especially for patients who could benefit from treatment with ATIR101. We filed a marketing authorization application (MAA) in 2017 with our phase 2 ATIR101 data and historical T-cell deplete haploidentical hematopoietic stem cell transplant (HSCT) control data based on input from EMA that these were considered adequate for review. Feedback from the EMA now indicates that the phase 2 data and historical T-cell deplete control data do not provide adequate support for a marketing authorization due to the evolution of the standard of care with the post-transplant cyclophosphamide (PTCy, aka Baltimore) protocol.”

Kiadis is currently enrolling a global, 250 patient, randomized phase 3 trial, comparing patients treated with ATIR101 after a T-cell deplete HSCT to patients treated with a T-cell replete haploidentical HSCT based on the PTCy protocol. Completion of enrolment and interim readout of the phase 3 study are expected in 2021. If positive, the study will be the basis for filing of a biologics license application (BLA) with the US Food and Drug Administration (FDA) and a new MAA with the EMA.

Mr. Lahr continued, “The randomized phase 3 trial, if positive, should address EMA’s concerns, as it compares ATIR101 to the current standard of care, the PTCy protocol. HSCT patients are in need of new treatment options and we will work diligently to advance our HSCT programs, while also pursuing cancer therapeutics with our NK-cell platform.”

Scott Holmes, CFO of Kiadis Pharma added, “We do not believe that this setback significantly changes the long-term revenue potential for ATIR or the near-term cash needs of Kiadis. Revenue expectations in the initial years of European launch were minimal and would not have provided a positive operating margin. Importantly, we planned for and are enrolling the phase 3 study necessary for potential regulatory approval in the United States, and now the European Union.”

About ATIR101 and KNK002

Kiadis has two cell-based therapeutics in development for patients with late-stage blood cancer undergoing a hematopoietic stem cell transplant: T-cell based ATIR101 and NK-cell based KNK002. Administered as adjunctive immunotherapeutics on top of HSCT, ATIR101 and KNK002 provide lymphocyte infusions with functional, mature and potent immune cells from a haploidentical family member. The T-cells in ATIR101 and NK-cells in KNK002 will help fight infections and remaining tumor cells until the immune system has fully re-grown from stem cells in the transplanted graft.

In ATIR101, T-cells that would cause GVHD are depleted from the donor lymphocytes, using our photodepletion technology. At the same time, ATIR101 contains potential cancer-killing T-cells from the donor that could eliminate residual cancer cells and help prevent relapse of the disease. Our NK-cell nanoparticle processing technology enables improved ex vivo expansion and activation of NK-cells supporting multiple high-dose infusions with potent anti-cancer cytotoxicity.

In addition, Kiadis is developing NK-cell based therapies for the treatment of relapse/refractory AML and has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors.

Kiadis Contacts:

Kiadis Pharma:
Amy Sullivan, SVP Corporate Affairs
Tel: +1 (508) 479-3480

Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514

About Kiadis

Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative cell-based therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities in the US and across Europe, Kiadis Pharma is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at

Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Record changed: 2019-10-23


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Kiadis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top